{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Not Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"description":"RECIST response categories: Progressive disease (PD): \\>=20% increase in sum of longest diameter (LD) of target lesion(s), taking as reference smallest sum LD recorded since treatment started. Complete response (CR): disappearance of all target lesions. Partial response (PR): \\>=30% decrease in sum of LD of target lesion(s), taking as reference baseline sum LD. Stable disease (SD): neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD.","groups":[{"description":"Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.","id":"OG000","title":"Pemetrexed/Oxaliplatin"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"at 8 weeks","title":"Patient Response to Treatment Measured by RECIST Criteria","type":"PRIMARY","unitOfMeasure":"participants"}